Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BioNTech

Pfizer COVID shot seems protective for children under 5 in early data

Pfizer Inc. and BioNTech SE said their COVID-19 vaccine was highly effective and prompted a strong immune response in children under age 5, based on early results from a trial that is likely to pave the way for infants and toddlers to finally get immunized.

Tribune News Service

Covid vaccine: Pfizer says three doses enough to protect children under 5

Three doses of Pfizer’s Covid-19 vaccine will offer strong protection for children younger than 5, the company announced on Monday.

Evening Standard

Pfizer/BioNTech say 3 COVID shots elicit good response in children under 5

Drugmakers Pfizer Inc and BioNTech SE said on Monday that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.

Reuters

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer says 3 COVID shots protect children under 5

Pfizer says three small doses of its COVID-19 vaccine protect kids under 5 and that it plans to give the data to U.S. regulators later this week

The Independent UK

Omicron infection turbo-charges vaccinated people’s immunity: study

People who are vaccinated and then get infected with Omicron may be primed to overcome a broad range of coronavirus variants, early research suggests.

Bangkok Post

Where BioNTech Stands With Analysts

Within the last quarter, BioNTech (NASDAQ:BNTX) has observed the following analyst ratings:

Benzinga

Why BioNTech Stock Is Rising Today

BioNTech SE (NASDAQ: BNTX) shares are trading higher Monday after the company reported financial results and reaffirmed its 2022 outlook.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

BioNTech's Revenue Triples On Omicron Demand For Its Pfizer-Partnered Covid Shot

BioNTech's first-quarter revenue tripled on the back of its Pfizer-partnered Covid vaccine, leading BNTX stock to pop Monday.

Investors Business Daily

BioNTech Clocks Over $6B In Q1 Sales, Sticks To FY22 Guidance

BioNTech SE (NASDAQ:BNTX) has reported Q1 FY22 revenues of €6.37 billion compared to €2.05 billion a year ago, mainly due to high demand for the company's COVID-19 vaccine. In Q1 FY22, BioNTech and its partner Pfizer Inc (NYSE:PFE) have invoiced approximately 750 million COVID-19 vaccine doses. As of end-April 2022, the companies have signed orders…

Benzinga

How To Attend BioNTech Q1 2022 Earnings Conference Call

BioNTech (NASDAQ:BNTX) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. How to Attend BioNTech (BNTX) Conference Call Follow this link to access the live webcast.

Benzinga

Pfizer accused of Covid profiteering as first-quarter sales hit $26bn

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill

The Guardian - UK

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Another delay for five-and-under vaccine

The issue isn't around safety, but instead messaging and vaccine effectiveness

Salon

What's Happening With BioNTech SE Shares?

Shares of vaccine companies, including BioNTech SE - ADR (NASDAQ: BNTX), are trading higher amid COVID-19 concerns due to rising cases in China.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

If You Invested $1,000 In BioNTech Stock At Its Pandemic Low, Here's How Much You'd Have Now

Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than others since the pandemic bottom.

Benzinga

Pfizer/BioNTech's COVID-19 Vaccine Booster Shows High Immune Response In Kids Aged 5-11 Years

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced results from a Phase 2/3 trial of a 10 µg booster (third) dose of COVID-19 vaccine in children aged 5-11 years.

Reuters

Pfizer/BioNTech say booster dose increases protection vs Omicron in kids aged 5-11

A third dose of the COVID-19 vaccine from Pfizer Inc and BioNTech produced significant protection against the Omicron variant of the coronavirus in healthy children ages 5 to 11, the companies said on Thursday.

Benzinga

HC Wainwright Reiterates Buy Rating On BioNTech, While Lowers Price Target

HC Wainwright has reiterated its Buy rating on BioNTech SE (NASDAQ: BNTX) while reducing the price tar

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Expert Ratings for BioNTech

Within the last quarter, BioNTech (NASDAQ:BNTX) has observed the following analyst ratings:

Investors Business Daily

Covid Proved Their Tech, But Moderna, BioNTech Face A New Battle

Demand for Covid boosters is waning, according to a recent IBD/TIPP Poll, which sheds some light on continued pressure for vaccine stocks.

Benzinga

Matinas BioPharma Inks mRNA-Based Vaccine Pact With BioNTech

BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have

Benzinga

Here's Why Matinas BioPharma Shares Are Rising

Matinas BioPharma Holdings Inc (NASDAQ: MTNB) shares are trading higher by 10.4% at $0.86 after the company and BioNTech announced an exclusive research collaboration to evaluate novel delivery technology for mRNA-based vaccines.

The Independent UK

Sadiq Khan calls on leading vaccine manufacturers to share Covid jab blueprints with world

Exclusive: Sadiq Khan, alongside mayors of New York and Johannesburg, urged companies ‘to do all you can’ to promote vaccine equity and ‘help stop the unnecessary loss of life’

Investors Business Daily

Moderna, BioNTech Dive As Israel Study Looks Bearish On Fourth Covid Shot

Vaccine stocks toppled Wednesday after an Israeli study suggested immunity wanes quickly following a second Covid booster shot.

Benzinga

mRNA Vaccine Maker CEOs Pocketed $100M In Pandemic Pay: FT

The CEOs of Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) have sha

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

University of Washington

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.